INTRODUCTION
Primary myelofibrosis (PMF) is a chronic myeloproliferative neoplasm (MPN) that, with essential thrombocythemia and polycythemia vera, constitutes a heterogeneous group of Philadelphia-negative clonal hematopoietic stem cell (HSC) disorders associated with overproduction of mature myeloid cells. Typical traits of myelofibrosis are an increased proliferation of megakaryocytes, a deposition of fibrosis in the bone marrow, an abnormal stem cell trafficking and an extramedullary hematopoiesis (myeloid metaplasia). Moreover, PMF is associated with an increased risk of thrombosis and/or an extramedullary hematopoiesis (myeloid metaplasia). Moreover, PMF is associated with an increased risk of thrombosis and/or extramedullary hematopoiesis (myeloid metaplasia). Furthermore, it has been demonstrated that most of these genes are associated with age-related clonal hematopoiesis in normal elderly subjects, suggesting that pre-malignant clones may be present many years before disease develops and are required, but insufficient, to result in disease.17,18

microRNAs (miRNAs) have an important role in the regulation of hematopoiesis.19–22 Our group demonstrated that miR-16-2 contributes to the expansion of erythroid lineage in polycythemia vera23 and we showed that miR-155-5p is pathogenically associated to MK hyperplasia in PMF through JARID2 downregulation.24 Moreover, we recently characterized miRNA and microRNA offset RNAs (moRNA) expression in SET2 cells25 and in CD34+ stem cells using massive small RNA-seq. In the latter study, we observed specificity in small RNAs expression of PMF cells.26 Although these findings are supportive of the involvement of miRNAs in MPF pathobiology, our understanding of miRNAs involvement in MPNs is still limited.27 A deeper characterization of the miRNA-mediated pathogenesis processes19,28 would be highly desirable in order to identify suitable concurrently targetable pathways amenable to therapeutic intervention.28,29

ORIgINAL ARTICLE
A data-driven network model of primary myelofibrosis: transcriptional and post-transcriptional alterations in CD34+ cells

E Calura1,6, S Pizzini1, 2, 6, A Bisognin3, A Coppe5, G Sales1, E Gaffo3, T Fanelli2, C Mannarelli4, R Zini2, R Norfo5, V Pennucci5, R Manfredini5, C Romualdi1, P Guglielmelli4, AM Vannucchi4,7 and S Bortoluzzi3,7 on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative (AGIMM) Investigators6

microRNAs (miRNAs) are relevant in the pathogenesis of primary myelofibrosis (PMF) but our understanding is limited to specific target genes and the overall systemic scenario is lacking. By both knowledge-based and ab initio approaches for comparative analysis of CD34+ cells of PMF patients and healthy controls, we identified the deregulated pathways involving miRNAs and genes and new transcriptional and post-transcriptional regulatory circuits in PMF cells. These converge in a unique and integrated cellular process, in which the role of specific miRNAs is to wire, co-regulate and allow a fine crosstalk between the involved processes. The PMF pathway includes Akt signaling, linked to Rho GTPases, CDC42, PLD2, PTEN crosstalk with the hypoxia response and Calcium-linked cellular processes connected to cyclic AMP signaling. Nested on the depicted transcriptional scenario, predicted circuits are reported, opening new hypotheses. Links between miRNAs (miR-106a-5p, miR-20b-5p, miR-20a-5p, miR-17-5p, miR-19b-3p and let-7d-5p) and key transcription factors (MYCN, ATF, CEBPA, REL, IRF and FOXJ2) and their common target genes tantalizingly suggest new path approaches to approach the disease. The study provides a global overview of transcriptional and post-transcriptional deregulations in PMF, and, unifying consolidated and predicted data, could be helpful to identify new combinatorial therapeutic strategy. Interactive PMF network model: http://compgen.bio.unipd.it/pmf-net/.

Blood Cancer Journal (2016) 6, e439; doi:10.1038/bcj.2016.47; published online 24 June 2016

1Department of Biology, University of Padova, Padova, Italy; 2Centre for Integrative Biology (CIBIO), University of Trento, Trento, Italy; 3Department of Molecular Medicine, University of Padova, Padova, Italy; 4Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy and 5Department of Life Sciences, University of Modena and Reggio Emilia, Modena, Italy. Correspondence: Professor S Bortoluzzi, Department of Molecular Medicine, CIBIBI Biotechnology Center, University of Padova, via G. Colombo 3, Padova 35131 Italy. E-mail: stefania.bortoluzzi@unipd.it
6These authors contributed equally to this work.
7These authors contributed equally to this work.
8Members of the AGIMM are listed before References.
Received 6 May 2016; accepted 19 May 2016
Thereby, the aim of this study was to obtain an informative, composite and interactive data-driven picture of pathways and circuits deregulated in PMF. We used a composite pipeline exploiting both ‘knowledge-based’ and ab initio approaches to discover mixed transcriptional and post-transcriptional deregulated circuits in PMF. This strategy allowed us to describe an unforeseen picture of miRNA and gene regulatory circuits linked to abnormal cellular functions and pathways.

METHODS
Patient selection and expression data
For this study, we considered miRNA and gene expression data (series GSE41812 and GSE53482) obtained by analyzing CD34+ cells of 42 patients with a diagnosis of PMF and 16 peripheral blood (CTR PB) and 15 bone marrow (CTR BM) samples from normal donors. Primary myelofibrosis patients were in a typical fibrotic stage of the disease according to the WHO, and were molecularly characterized (JAK2V617F, MPLW517F, CALR mutations). See Norfo et al.24 for additional clinical information about patients.

Gene expression profiling, obtained by Affymetrix HG-U219, and annotated using custom CDF,20 HG-U219_Hs_ENTREG version 14, was normalized by RMA procedure. A log2 expression matrix with 18,654 genes and 73 samples was obtained.

MiRNA expression profiling, obtained by Affymetrix miRNA 2.0 microarray, was analyzed by using a modified RMA procedure: the background subtraction was performed considering all species and controls of the chip, while normalization and summarization were calculated only on human probe sets, using a custom-designed CDF. MiRNA names were translated to updated miRBase names filtering out deprecated miRNAs, using the custom annotation package AffyIDs. A log2 expression matrix of 584 miRNAs and 73 samples was obtained after filtering miRNAs weakly expressed (lowest 25% of average expression level) and/or poorly variable across samples (Shannon Entropy < 1.4).

Identification of negatively correlated predicted targets of miRNAs
We identified the predicted regulatory relations supported by our expression data by integrating target predictions and expression profiles. Target predictions were computed with TargetScan-62 algorithm according sequence similarity with conservation (threshold at 0.8).

Pairwise Pearson correlations between miRNA and predicted target gene expression profiles were calculated. The relationships supported by significant anti-correlation (r < −0.5 with FDR < 0.1) were considered for the following analyses.

The miRNA/target interactions involving genes annotated in KEGG pathways have been used in the following Micrographite pipeline.

Pathways-derived circuits
Two comparisons were considered for the analysis: PMF vs CTR BM and PMF vs CTR PB. miRNA and miRNA relations involved in PMF were compared to CTR PB or CTR BM and have been identified using the Micrographite pathway analysis.23 In the following we will report a brief description of the main steps of the method; for details refers to Calura et al.31

KEGG pathways as stored in graphite Bioconductor package33 were enriched with validated and predicted miRNA-target interactions. We consider ‘validated interactions’ those interactions extracted from miTarBase26 and miRecords27 for which reporter assays have been provided in literature, while the ‘predicted/supported interactions’ are the in silico predicted miRNA-mRNA couples filtered by anticorrelation of expressions as discussed above. In this step, only miRNAs targeting genes already annotated in the cell pathways have been added. Following the Micrographite pipeline, the pathways resulted to be significant at the whole pathway level (q-value for the mean and variance tests < 0.1) were used for the second step of the analysis that identifies, within each significant pathway, the subportion of the pathway (hereafter called path) mostly associated to the phenotype. The merge of the top 10 paths is called meta-pathway. The meta-pathway is then re-analyzed in order to find the top scored paths. Finally, the paths that, ranked by scores, belong to upper quartile are considered as the most involved and reported. The Micrographite analysis has been performed independently for each comparison (PMF vs CTR PB; PMF vs CTR BM) and the two final networks have been merged into a single network.

Mixed miRNA-TF-gene circuit identification
In parallel, the expression data of genes that are present in the KEGG pathways were used with the miRNAs profile as input of Magia2. Magia2 (http://gencomp.bio.unipd.it/magia2) reconstrusts circuits involving positive and negative correlations between miRNAs, transcription factor (TFs) and target genes. It uses experimentally validated TF-miRNA relations obtained by miGen2.0 and TransmiR, and TF-gene relations obtained by the UCSC human genome annotation.

Target predictions were computed with TargetScan (score threshold at 0.8, top 25% of the predictions distribution) and Pearson’s correlation coefficient was used as correlations measure (threshold at 0.5).

Pathways visualisation
Network visualization and annotation have been performed using Cytoscape (version 3.1).

Validation of differentially expressed sRNAs
We performed individual miRNAs assay by Taqman quantitative real-time PCR for quantification of abnormally expressed miRNAs in PMF and control granulocytes and plasma. All samples were processed within 4 h after collection. Plasma, collected by peripheral blood centrifugation in tubes containing EDTA (4 °C; 3000 revolutions per minute for 15 min, then 6000 revolutions per minute for 5 min), was stored at −80 °C in RNase/DNase-free Eppendorf tubes. RNA was isolated and eluted in 20 μl of RNase-free water using a miRNeasy Serum/Plasma Kit (Qiagen). For miRNA expression assays 8 μl eluted RNA was used.29 CDNA was synthesized from total RNA using miRNA-specific RT primers contained in the TaqMan microRNA Human Assays (Applied Biosystems, Foster City, CA, USA). Briefly, single-stranded cDNA was synthesized from 10 ng total RNA in 15-μl reaction volume with the High-Capacity cDNA Archive Kit (Applied Biosystems) using 1 μl deoxynucleobonucleoside triphosphates, 50 U Multiscribe reverse transcriptase, 3.8 U RNase Inhibitor and 50 nM of miR-specific RT primers. The reaction was incubated at 16 °C for 30 min followed by 30 min at 42 °C, and inactivation at 85 °C for 5 min. Each generated cDNA was amplified by quantitative real-time PCR with sequence-specific primers from the TaqMan microRNA Assays on an ABI Prism 7300 real-time PCR system (Applied Biosystems). PCR reactions included 10 μl 2 × Universal PCR Master Mix (No AmpErase UNG), 2 μl each 10 × TaqMan MicroRNA Assay Mix and 1.5 μl reverse-transcribed product; they were incubated in a 96-well plate at 95 °C for 10 min, followed by 40 cycles of 95 °C for 15 s and 60 °C for 1 min. Expression variations were calculated using the RQ method and a t-test P-value of 0.05 was used as threshold to identify differentially expressed elements.

RESULTS AND DISCUSSION
A systems biology pipeline identifies deregulated signaling pathways in PMF patients
We considered matched expression profiling data of 584 miRNAs and 18,654 genes in 73 CD34+ cells sampled from 42 PMF patients, and 31 samples from normal subjects (15 from bone marrow (CTR BM) and 16 from peripheral blood (CTR PB). The study grounds on comparative analysis of CD34+ cells of PMF patients compared with control CD34+ from normal donors. In a previous study, specificities of both gene and miRNA expression profiles were observed comparing peripheral blood and bone marrow control samples,24 confirming known differences between these populations. Thus, peripheral blood and bone marrow control samples were considered separately, for parallel comparisons with PMF samples, to avoid biases due to control samples inhomogeneity, and to obtain more informative results. Then, a union of the comparisons gave a global picture. The flowchart in Figure 1 provides a summary of the procedure.

We obtained 250 interactions in the PMF vs CTR BM (54 miRNAs and 236 gene targets involved) and 442 in the PMF vs CTR PB (43 miRNAs and 428 genes) using MAGIA2. Then, the miRNA and gene expression profiles of PMF patients have been independently compared with CTR BM and CTR PB health samples using Micrographite. Supplementary Tables 1-8 contain all the intermediate data of the two analyses whereas a brief comparison of results is summarized in Supplementary Figures 1 and 2. The
resulting networks of the two analyses were merged achieving a set of 181 non-redundant genes and miRNAs and their interactions that represent the compendium of the deregulated pathway-guided interactions in PMF. The network contains a selection of 401 gene-gene consolidated interactions from KEGG pathways, 45 miRNA-gene connections already validated with gene reporter assays and only one in silico predicted anti-correlated miRNA-gene connection (Figure 2a).

In this way, we obtained the network, consisting of 620 edges and 220 nodes (of which 34 are miRNAs; Table 1); they are reported, and are included in the yellow area of the circuit in Figure 2a. Table 1 summarizes miRNAs and TFs involvement. Magia² circuits showed that six miRNAs and six TFs seem to play critical roles in the regulation of transcription in PMF (Figure 2a and Table 1). Almost all of the miRNAs are components of the let-7 family (miR-10a-5p, miR-20a-5p, miR-20b-5p, miR-17-5p and miR-19b-3p). The upregulation of the latter miRNA in PMF CD34+ cells has been previously validated. Mixed miRNA-TF circuits connect to altered pathways miRNAs post-transcriptionally regulate gene expression, also by alteration of target miRNAs stability. Moreover, TFs modulate the expression of miRNAs and of target genes at transcriptional level, creating a regulatory network. Magia² analysis identified mixed regulatory circuits composed of miRNAs, TFs and target genes, considering in parallel expression profiles in PMF and CTR BM samples and in PMF and CTR PB samples. For each type of control samples used, Supplementary Tables 9–12 report more details on observed correlation values, on the numbers of identified circuits, on predicted interactions and on involved genes and miRNAs. Inferred interplay of miRNAs and TFs in gene/transcripts expression regulation may comprise two types of mixed regulatory circuits: (i) a TF regulates both a miRNA and a gene promoter, and the same miRNA targets the gene mRNA exerting post-transcriptional regulation; (ii) a miRNA post-transcriptionally regulates both a gene encoding a TF and another gene, that on turn is a transcriptional target of the TF. For both mixed circuits topologies, different combinations of positive and negative pairwise correlations should correspond to activatory and inhibitory interactions giving rise to coherent or incoherent feed forward loops. Since circuits based on strongest interactions are particularly trustable and may highlight key regulatory relations, we focused on circuits that had absolute correlation at least 0.5 for all the three types of interactions (miRNA-target gene, TF-miRNA, TF-target-gene). PMF vs CTR PB comparison identified 169 interactions, involving 63 nodes, 6 miRNAs and 57 genes. No significant circuits were selected for PMF vs CTR BM comparison.

Pathway annotations are progressively manually updated but, even if enriched with miRNA validated interactions, they are still incomplete. Thus, we enriched the pathway-based networks with nodes and relations coming from selected Magia² circuits, that shared with the first network at least one gene or one miRNA. In this way, we obtained the network, consisting of 620 edges and 220 nodes (of which 34 are miRNAs; Table 1); they are reported, with different details and annotation, in Supplementary Figure 3 and are included in the yellow area of the circuit in Figure 2a.
Figure 2. PMF network model. (a) PMF network integrating pathway-derived miRNA-gene networks deregulated in PMF and mixed TF-miRNA-gene circuits discovered by reverse engineering of expression data. The network (see Supplementary Figure 3 for a larger version) gives a non-redundant and comprehensive picture of most modulated paths in the two PMF vs CTR comparisons, of the impact of miRNAs on pathway genes, and of connected TF-miRNA-gene mixed circuits discovered in the study. Genes are reported as round rectangles, transcription factors as diamonds and miRNAs as triangles. Node colors represent the fold-change (FC) of the gene expressions in the PMF vs CTR BM (node inner color) and PMF vs CTR PB (node border color). The type of edges depends on the type of interaction: arrow for activation, T arrow in case of inhibition, and arrow line for miRNA-target predicted/supported interactions. The light blue shade indicates the part of the network resulting from miRNA and gene topological pathway analysis. The yellow shade indicates mixed TF-miRNA-gene circuits, inferred by Magia2 analysis, connected to the path-derived network. (b) Cluster analysis of expression profiles of miRNAs and genes included in the final PMF network do not show clustering of PMF patients by mutation. Samples are colored according to the carried mutation as shown in the legend (3N indicates triple negative). Sample clustering was obtained according to Euclidean distance and complete clustering. See Supplementary Figure 4 for the corresponding heatmap. (c) Summary of most deregulated pathways represented in the miRNA-gene network, and connections thereof. See http://compgen.bio.unipd.it/pmf-net/ for an interactive, searchable and zoomable version of the PMF network model.
deregulated elements and relations thereof, that are common to all PMF patients, independent of the underlying driver mutation. Accordingly, fold-changes against control cells have been recalculated stratifying patients by driver mutations; these data do not show mutation-specific contributions in the here presented network (Supplementary Figure 5).

Confirmation of mRNA and gene differential expression in PMF Genes and miRNAs are included in the PMF network only if they have shown coordinated expressions across patients and opposite behaviors if compared to healthy donors. Specifically, modulated genes and miRNA are included in the PMF network if they are either linked according to validated relations (pathway-derived part of the network and TF-gene or TF-miRNA relations in the part containing MAGIA2 circuits) or linked by predicted miRNA-target relations that are anyway significantly supported by expression data analysis.

Even if the multistep approach we used for the PMF network reconstruction was specifically designed to go beyond the differential expression of single genes or miRNAs, giving a more informative picture of the impact of miRNAs deregulated in PMF to pathways and to mixed connected regulatory circuits it is worth noting that we obtained confirmation of the differential expression in PMF samples compared to controls for 13 miRNA and 5 genes included in the network, giving further support to our results. As detailed in Table 2, in addition to the confirmation of differential expression in CD34+ previously obtained by array and quantitative real-time-PCR and RNA-seq, we also conducted new experiments in granulocytes and plasma (see Methods) to obtain new insights of direct translational relevance. These confirmed a significant upregulation (P-value < 0.05) of miR-195-5p, miR-106a-5p, miR-145-5p, miR-17-5p, miR-185-5p, miR-195-5p in PMF patients granulocytes (GR; considering 50 PMF patients and 10 healthy controls), miR-19b-3p both in PMF granulocytes and plasma (25 PMF patients and 6 controls) and of miR-29b-3p in plasma.

Candidate transcriptional deregulated pathways of PMF Figure 2c summarizes the main alterations of the transcript levels observed in PMF patients, involving key pathways and connected circuits, as discussed below in more detail with the support of Figure 3.

Akt signaling. One of most deregulated pathways is the Akt signaling, a part of the Phosphoinositide-3 kinase/protein kinase-B/mammalian target of Rapamycin (PI3K/Akt/mTOR) pathway (Figure 3a). As theJak/STAT signaling path, the Akt signaling is triggered by receptor tyrosine kinases that increase PI3K levels, activating AKT, phosphorylating several targets including mTOR. Several tumor suppressor genes, as PTEN, interact with this path. PI3K/AKT/mTOR is a central signaling module and several other pathways converge on it regulating cell survival and proliferation. It is constitutively activated in MPNs and also in other cancers. Small molecular inhibitors of this pathway are available in clinics, and evidence of activity of an mTOR inhibitor (Everolimus) in myelofibrosis patients has been provided. The contribution of PI3K/mTOR pathway to MPN pathogenesis has received strong experimental support.

Rho GTPases, CDC42, PDL2 and PTEN. The PMF network shows deregulation of Rho GTPases (Figure 3b), intracellular signal transducers, members of the RAC subfamily of Rho GTPases. Deregulation of GEFs (guanine nucleotide exchange factors), recharging Rho GTPases and determining their spatial-temporal activity is also displayed. Interaction of stem cell factors and adhesion molecules with their receptors (c-Kit, CXCR4 and Integrins) expressed by the HSCs triggers the activation of GEFs. Rho GTPases could affect also cancer progression, both as oncogene and oncosuppressor. Specifically, CDC42 and RAC2 control homeostasis of blood cell production by hematopoietic stem/progenitor (HSC/P) cells balancing HSC/P retention within the bone marrow and migration in the blood.

CD42, highly downregulated in PMF, regulates cell polarity and cell cycle progression. Its deletion affects the number of early myeloid progenitors while suppressing erythroid differentiation. CDC2-deficient mice develop a fatal myeloproliferative disorder manifested by significant leukocytosis with neutrophilia, myeloid hyperproliferation and myeloid cell infiltration into distal organs. Downregulation of RhoA activity, as observed in PMF, resulted in increased HSC engraftment and self-renewal. In the network, CDC42 is connected with the upregulated miR-29a-3p, which we previously demonstrated is able to suppress their expression and which is connected also to the phosphatase PTEN, regulated by RhoGTPases. In turn, PTEN, downregulated in PMF (and linked to several miRNAs including the upregulated miR-19a-3p, miR-29a-3p and miR-21-5p), modulates intracellular levels of PI3K in cells, functioning as a tumor suppressor. The upregulation in PMF of miRNAs interacting with PTEN was previously established.

### Table 1. miRNAs impacting in pathway-derived miRNA-gene networks deregulated in PMF and participating to mixed TF-miRNA-gene circuits

| Main pathways and genes | miRNAs |
|-------------------------|--------|
| Ca(2+) signaling        | miR-125b-5p |
| CDC42                   | miR-133a |
| CDC42                   | miR-185-5p |
| PTEN signaling          | miR-124-3p |
| PTEN-GEF crosstalk      | miR-124A-5p |
| PTEN-CDC42 crosstalk    | miR-146A-5p |
| RAS/PTEN crosstalk      | miR-146B-5p |
| RAS/RAS signaling       | miR-196B-5p |
| RAS/RAF signaling, GEF activity | miR-98-5p |
| RHOC                     | miR-7-5p |
| RHOC, MAPK and NF-kappaB signaling | let-7a-5p |
| MYC                     | let-7d-5p |
| MYC                     | miR-106a-5p |
| REL, CEBPA, FOXO2, MYC, IRF1 | miR-106a-5p |
| mTOR                     | miR-145-5p |
| mTOR, AKT                | let-7d-5p |
| mTOR, AKT                | miR-19a-3p |
| mTOR, AKT                | miR-19b-3p |
| mTOR, AKT                | miR-19b-5p |
| mTOR, AKT                | miR-20a-5p |
| mTOR, AKT                | miR-21-5p |
| mTOR, AKT                | miR-221-5p |
| mTOR, AKT                | miR-222-5p |
| mTOR, AKT                | miR-26a-5p |
| mTOR, AKT                | miR-494 |
| mTOR, AKT                | miR-519d |
| mTOR, AKT                | miR-93-5p |
| mTOR, AKT                | miR-17-5p |
| mTOR, AKT                | miR-29a-3p |
| mTOR, AKT                | miR-29b-3p |
| mTOR, AKT                | miR-29c-3p |
| mTOR, AKT                | miR-31-5p |
| mTOR, AKT                | miR-155-5p |

Abbreviations: miRNA, microRNA; PMF, primary myelofibrosis; TF, transcription factor. The upper part of the table indicates the pathways or genes targeted by miRNAs in PMF; the lower part of the table indicates the transcription factors for which the interplay with miRNAs has been in silico inferred.
is also connected with miR-29b-3p, miR-29c-3p and miR-185-5p, the latter linked also with the downregulated RHOA.

Another element markedly deregulated in the PMF network is Phospholipases D, PLD1 and PLD2 (Figure 3b). Phospholipase D and its product PA (Phosphatidic Acid) have been implicated in many physiological and pathological functions, such as cancer cell invasion and metastasis. PLD2 is dual activity enzyme with both lipase and GEF activities for the Rac2 and RhoA GTPases. This lipase-GEF duality has important biochemical and cellular implications and new PLD inhibitors have inhibiting GEF activity.54 This lipase-GEF duality has important biochemical and cellular implications and new PLD inhibitors have inhibiting GEF activity.54

**HIF-1α pathway.** In connection with previously mentioned pathways, we found evidence of modulation of the HIF-1α hypoxia pathway (Figure 3c). As shown, both growth factors and oncogenic signaling can trigger an HIF-1α response, with the PI3K/Akt and Ras/Raf/MAPK pathways mediating upregulation of HIF-1α by increasing HIF-1α protein synthesis or stability, resulting in a modified transcriptional activity of HIF-1. In our network, the predicted/supported relation of the still poorly characterized miR-1244 (downregulated in PMF) with NOS3 (nitrergic oxide synthase 3, endothelial cell) is connected with HIF-1α while the upregulated miR-20a-5p connects HIF-1α to PTEN. NOS3 synthesizes nitric oxide, that is involved in several processes such as muscle relaxation, inhibition of platelet aggregation and leukocyte adhesion, with both vasodilatatory and antithrombotic properties. A recent study showed that NOS3 Glu298Asp polymorphism in homozgyosis increased the risk of thrombosis in a cohort of patients with essential thrombocythemia or prefibrotic PMF.56,57

A link between hypoxia and the activation of the HGF/Met axis, through the oxygen sensor HIF-1α in MPNs, has recently been proposed by Boisnoin and colleagues. Oxygen tension is as low as 1% in normal bone marrow and the hypoxic condition may result even more stringent because of the bone marrow hypercellularity in myelofibrosis. In accordance with our results, showing activation of the HIF-1α downstream genes (Figure 3c) and of NF-kB signaling (Figure 3a), the authors proposed that the activation of the HGF/Met axis, due to bone marrow or and exposure to inflammation cytokines (NF-kB-mediated activation), leads to enhanced survival and proliferation of mutated myeloid progenitors and increased production of various cytokines responsible for inflammation, neo-angiogenesis and fibrosis. Thus, molecules efficient at blocking NF-kB and HIF-mediated activation might represent an efficient therapy for MPNs by simultaneously blocking the cascade of inflammation cytokines, their signaling and the hematopoietic clone.

**Calcium and cyclic AMP signaling.** The upper part of the network in Figure 2a includes genes, belonging to Calcium signaling path (Figure 3d). More specifically, this part of the network includes genes encoding several subunits of calcium channel voltage-dependent, and other genes, including ATF/CREB subunits activated by cyclic AMP-dependent protein kinases, tightly related to MAPK and Ras signaling pathways, Chemokine signaling and Apoptosis. ATF/CREB genes participate also to PI3K/Akt signaling (Figure 3a), the authors proposed that the activation of the HGF/Met axis, due to bone marrow or and exposure to inflammation cytokines (NF-kB-mediated activation), leads to enhanced survival and proliferation of mutated myeloid progenitors and increased production of various cytokines responsible for inflammation, neo-angiogenesis and fibrosis. Thus, molecules efficient at blocking NF-kB and HIF-mediated activation might represent an efficient therapy for MPNs by simultaneously blocking the cascade of inflammation cytokines, their signaling and the hematopoietic clone.

### Table 2. miRNAs and genes included in the network for which differential expression in PMF patients compared to healthy controls has been confirmed

| PMF vs CTR | CD34+ | GR and Plasma |
|------------|-------|---------------|
| Arrays     | RNA-seq | RT-PCR | RT-PCR (PMF vs CTR; RQ mean ± dev) |
| miR-106a-5p | UP     | UP     | UP GR (1.9 ± 1.2 vs 1.08 ± 1.0) |
| miR-145-5p | UP     | UP     | UP GR (1.7 ± 0.9 vs 1.0 ± 0.5) |
| miR-146b-5p| UP     | UP     | UP GR (1.5 ± 0.7 vs 1.1 ± 0.9) |
| miR-155-5p | UP     | UP     | UP GR (3.0 ± 3.1 vs 1.5 ± 1.2) |
| miR-17-5p  | UP     | UP     | UP GR (15.3 ± 10.5 vs 1.8 ± 2.1) |
| miR-185-5p | UP     | UP     | UP GR (15.3 ± 10.5 vs 1.8 ± 2.1) |
| miR-195-5p | UP     | UP     | UP Plasma (12.4 ± 17.5 vs 1.37 ± 0.95) |
| miR-19a-3p | UP     | UP     | UP Plasma (12.4 ± 17.5 vs 1.37 ± 0.95) |
| miR-19b-3p | UP     | UP     | UP Plasma (3.0 ± 1.5 vs 1.5 ± 1.2) |
| miR-21-5p  | UP     | UP     | UP Plasma (12.4 ± 17.5 vs 1.37 ± 0.95) |
| miR-29-3p  | UP     | UP     | UP Plasma (3.0 ± 1.5 vs 1.5 ± 1.2) |
| miR-29c-3p | UP     | UP     | UP Plasma (3.0 ± 1.5 vs 1.5 ± 1.2) |
| miR-494-3p | UP     | UP     | UP Plasma (3.0 ± 1.5 vs 1.5 ± 1.2) |
| ANGPT1     | UP     | UP     | UP Plasma (3.0 ± 1.5 vs 1.5 ± 1.2) |
| ARIHEF7    | DOWN   | DOWN   | DOWN |
| CDC42      | DOWN   | DOWN   | DOWN |
| MEF2D      | DOWN   | DOWN   | DOWN |
| SMAD7      | DOWN   | DOWN   | DOWN |

Abbreviations: miRNA, microRNA; PMF, primary myelofibrosis. The second column indicates if miRNAs and genes resulted up- or down-regulated according to array data used for network reconstruction. The following columns indicate for which elements a significant differential expression has been previously confirmed using RNA-seq in CD34+ cells, and using RT-PCR in CD34+ cells, in granulocytes (GR) and in plasma samples.
PMF compared to controls and not present in the network (PMF equal to CTR PB controls and only slightly upregulated in PMF in comparison to CTR BM controls) evidencing that genetic alterations of PMF patients do not affect significantly the transcriptional behavior of the CALR gene. However, many CALR interactors and genes participating in CALR-involving pathways are represented in the PMF network: ATF4 and ATF6 participate to unfolded proteins response (Protein processing in endoplasmic reticulum), and transduce to the nucleus ER stress, eventually inducing apoptosis; CD209 and RAC1 participate to the Phagosome; several genes, including FOS/JUN and NFKB are in the Chagas disease path; ATF2/CREB, NFAT, EP300 and RAS genes share with CALR the HTLV-1 infection path.

The Ca^{2+}-related part of the net is connected to the TFs ATF2 and CREB. Several circuits show cross-talk of ATF2 and let-7d-5p, both downregulated in PMF, to 12 correlated genes, mostly downregulated in PMF (RNF7, HIC1, HIC2, PRKACG, PRKX, PRKACA, PRKACB, MEF2D, ARMCB, KLF9, ZNF516). Among them HIC1/2 are tumor suppressor genes, known to be hypermethylated in cancer and in high-risk myelodysplastic syndromes. ZNF516 is a zinc-finger protein that interacts with epigenetic regulation protein such as HDAC1 and KDM1A. The upregulated PLXND1 is one of Semaforin receptors, often highly expressed in cancer, that regulates tumor cell survival by suppressing an apoptotic pathway and seems to controls angiogenesis in cancer. let-7d-5p has also correlated expression with MYC with which its shares KLF13 as putative target. CREB connects to miR-20a 5p and to MYC, and in turn to their common targets.

Predicted circuits open new hypotheses
All the deregulated pathways contain links to novel in silico predicted interactions that could help in the candidate selection in research. In support of the results consistency, a subset of de novo predicted interactions is known and validated, that is, the upregulated miR-17-5p, miR-106a-5p and miR-20b-5p with the downregulated CDKN1A. CDKN1A is an important intermediate by which p53 blocks proliferation in response to DNA damage, and it inhibits CDK activity, blocking cell cycle progression. The validated post-transcriptional regulatory relations are also linked to MYC (highly upregulated in PMF) transcriptional activity, which is known to stimulate the expression of onco-miR-17 family. These,
in turn suppress IRF1, a tumor suppressor TF that is downregulated in PMF and has important supported targets, as MAP3K2, GLIS3 and LRC1H, all downregulated.

Four upregulated miRNAs (miR-17-5p, miR-106a-5p miR-20a-5p and miR-20b-5p) are negatively correlated with the downregulated TF FOXJ2 (Forkhead box protein J2), forming triangular circuits with four genes including the upregulated PDZ and LIM domain 5 (PDLIMS5), recently identified as the main signaling molecule that, in the context of augmented AMPK activity and in connection with Rac1-mediated acting cytoskeleton reorganization, regulates cell migration, a key process in MPNs.

CONCLUSIONS

The network inferred in this work is a unique and integrated signaling pathway of PMF, in which the role of miRNA is to wire, co-regulate and allow a fine cross-talk between all the involved processes. Most deregulated pathways include Akt signaling, linked to Rho GTPases, CDC42, PLCδ2 and PTEN cross-talk with the hypoxia pathway, which highlights the extreme hypoxic status in PMF bone marrow. Novel hints on cyclic AMP signaling involvement jointly connected with Calcium-linked cellular processes were given. Moreover, mixed circuits involving miRNAs (miR-106a-5p, miR-20b-5p, miR-20a-5p, miR-17-5p, miR-19b-3p and let-7d-5p) connections with key TFs (MYCN, ATF, CEBPA, REL, IRF and FOXJ2) and their common target genes were reported, opening new hypotheses. The targeted picture of transcriptional deregulation can be used to improve current understanding of the molecular pathways involved in the disease and delineate new combinatorial therapeutic strategies.

CONFLICT OF INTEREST

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The authors declare no conflict of interest.

ACKNOWLEDGEMENTS

The study received funding by Fondazione Cassa di Risparmio di Padova e Rovigo Progetti di Eccellenza 2011/2012 (http://www.fondazionecarparo.it/english-version/) to SB, CR and PG; by Ministero dell’Istruzione, dell’Università e della Ricerca (http://www.istruzione.it/); PRIN 2010/11 (2010NYNS57_002) and FIRB 2011 (RBAP11CZKL) and by ‘Special Program Molecular Clinical Oncology 5 x 1000’ to Associazione Italiana per la Ricerca sul Cancro (http://www.airc.it/english/), and in the framework of the 6th Action of the Integrated Project ‘Special Program Molecular Clinical Oncology 5 x 1000’.

AUTHOR CONTRIBUTIONS

EC, SP, SB, PG, CR and AMV conceived the study. EC, SP, AB, GS, AC, EG, SB, CR developed analysis tools and contributed to the bioinformatics infrastructure. EC, SP and SB did data analysis. EC, SP, CR, AMV and PG wrote the manuscript. TF, CM, RZ, RN, VP, RM, PG and AMV contributed with patients, expression data and results interpretation. All the authors revised the manuscript.

REFERENCES

1. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neo-
   plasms: the 2008 World Health Organization criteria and point-of-care diagnostic 
   algorithms. Leukemia 2007; 22: 14–22.

2. Vannucchi AM, Guglielmelli P, Tefferi A. Advances in understanding and man-
   agement of myeloproliferative neoplasms. CA Cancer J Clin 2009; 59: 171–191.

3. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S et al. Acquired 
   mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. 
   Lancet Lond Engl 2005; 365: 1054–1061.

4. Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L et al. Widespread occurrence 
   of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 2005; 
   106: 2162–2168.

5. Lau WYY, Hannah R, Green AR, Göttgens B. The JAK-STAT signaling pathway 
   is differentially activated in CALR-positive compared with JAK2V617F-positive ET 
   patients. Blood 2015; 125: 1679–1681.

6. Mascarenhas J, Roper N, Chaurasia P, Hoffman R. Epigenetic abnormalities 
   in myeloproliferative neoplasms: a target for novel therapeutic strategies. Clin 
   Epigenetics 2011; 2: 197–212.

7. Cross NCR. Genetic and epigenetic complexity in myeloproliferative neoplasms. 
   Hematol Am Soc Hematol Educ Program 2011; 2011: 208–214.

8. James C, Ugo V, Le Couédic JP, Staerk J, Delhommeau F, Lacout C et al. A unique 
   clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. 
   Nature 2005; 434: 1144–1148.

9. Kralevics R, Passamonti F, Buser AS, Teo S-S, Tiedt R, Passweg JR et al. A gain-of-
   function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 
   352: 1779–1790.

10. Zhao R, Xing S, Li Z, Fu X, Li Q, Krantz SB et al. Identification of an acquired JAK2 
    mutation in polycythaemia vera. J Biol Chem 2005; 280: 22788–22792.

11. Klampfl T, Harutyunyan A, Berg T, Gisslinger B, Schalling M, Bagienski K et al. 
    Genome integrity of myeloproliferative neoplasms in chronic phase and during 
    disease progression. Blood 2011; 118: 167–176.

12. Vannucchi AM, Biamonte F. Epigenetics and mutations in chronic myeloprolifer-
    ative neoplasms. Haematologica 2011; 96: 1386–1402.

13. Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC et al. Somatic 
    CALR mutations in myeloproliferative neoplasms with unmutated JAK2. N Engl J 
    Med 2013; 369: 2391–2405.

14. Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD et al. 
    Somatic mutations of caleculin in myeloproliferative neoplasms. N Engl J Med 
    2013; 369: 2379–2390.

15. Tefferi A. Novel mutations and their functional and clinical relevance in myelo-
    proliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 
    2010; 24: 1128–1138.

16. Ottmann CA, Kent DG, Nangalia J, Silber Y, Wedge DC, Grinfeld J et al. Effect of 
    mutation order on myeloproliferative neoplasms. N Engl J Med 2015; 372: 
    601–612.

17. Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG et al. 
    Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J 
    Med 2014; 371: 2488–2498.

18. Xie M, Lu C, Wang J, McLellan MD, Johnson KJ, Wendl MC et al. Age-related 
    mutations associated with clonal hematopoietic expansion and malignancies. 
    Nat Med 2014; 20: 1472–1478.

19. Zhan H, Cardozo C, Raza A. MicroRNAs in myeloproliferative neoplasms. Br J 
    Haematol 2013; 161: 471–483.

20. Zhang L, Sankaran VG, Lodish HF. MicroRNAs in erythroid and megakaryocytic 
    differentiation and megakaryocyte-erythroid progenitor lineage commitment. 
    Leukemia 2012; 26: 2310–2316.

21. Báez A, Martín-Antonio B, Piruat JI, Barbado MV, Prats C, Álvarez-Ladener I et al. 
    Gene and miRNA expression profiles of hematopoietic progenitor cells vary 
    depending on their origin. Blood Marrow Transplant J Am Soc Blood Marrow 
    Transplant 2014; 20: 630–639.

22. Raghavachari N, Liu P, Barb JI, Yang Y, Wang R, Nguyen QT et al. Integrated 
    analysis of miRNA and mRNA during differentiation of human CD34+ cells 
    delineates the regulatory roles of microRNA in hematopoiesis. Exp Hematol 
    2014; 42: 14–27–2.

23. Guglielmelli P, Tozzi L, Bogani C, Iacobucci I, Ponziani V, Martinelli G et al. 
    Overexpression of microRNA-16-2 contributes to the abnormal erythropoiesis 
    in polycythaemia vera. Blood 2011; 117: 6923–6927.

24. Norfo R, Zini R, Pennucci V, Bianchi E, Salati S, Guglielmelli P et al. miRNA-miRNA 
    integrative analysis in primary myelofibrosis CD34+ cells: role of mir-155/JARID2 
    axis in abnormal megakaryopoiesis. Blood 2014; 124: e21–e32.

Blood Cancer Journal
Bortoluzzi S, Bisogno A, Biasiolo M, Guglielmelli P, Biamonte F, Norfo R et al. Characterization and discovery of novel miRNAs and mRNAs in JAK2V617F-mutated SET2 cells. Blood 2012; 119: e120–e130.

Guglielmelli P, Bisogno A, Saccornai C, Mannarelle C, Coppe A, Vannucchi AM et al. Small RNA sequencing uncovers new miRNAs and mRNAs differentially expressed in normal and primary myelofibrosis CD34+ cells. PLoS One 2015; 10: e0140445.

Ha J-S, Jung H-R. Up-regulation of microRNA 146b is associated with myelofibrosis in myeloproliferative neoplasms. Ann Clin Lab Sci 2015; 45: 308–314.

Bartalucci N, Guglielmelli P, Vannucchi AM. Rationale for targeting the PI3K/Akt/mTOR pathway in myeloproliferative neoplasms. Clin Lymphoma Myeloma Leuk 2013; 13(Suppl 2): S307–S309.

Mascarenhas J. MicroRNA control of signal transduction. Nat Rev Mol Cell Biol 2008; 9: 819–829.

Inui M, Martello G, Piccolo S. MicroRNA control of signal transduction. Nat Rev Mol Cell Biol 2008; 9: 819–829.

Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 2003; 13: 2498–2504.

Maczlan SA, Lawson J, Baik J, Guillaud M, CF-Y Poh, Garnis C. Differential expression of miRNAs in the serum of patients with high-risk oral lesions. Cancer Med 2012; 1: 268–274.

Inui M, Martello G, Piccolo S. MicroRNA control of signal transduction. Nat Rev Mol Cell Biol 2010; 11: 252–263.

Guglielmelli P, Barosi G, Rambaldi A, Marchioli R, Masciulli A, Tozzi L et al. Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase I/II study in patients with myelofibrosis. Blood 2011; 118: 2069–2076.

Bogani C, Bartalucci N, Martinelli S, Tozzi L, Guglielmelli P, Bosi A et al. mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms. PLoS One 2013; 8: e54826.

Bartalucci N, Tozzi L, Bogani C, Martinelli S, Rotunno G, Villeval J-L et al. Co-targeting the PI3K/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms. J Cell Mol Med 2013; 17: 1385–1396.

Nayak RC, Zhang Q, Saqib KM, Schreve H, Macura K, Anderson KE et al. PLD1 rather than PLD2 regulates phospholipid-ester- and adhesion-dependent and Fc(γ)R-receptor-stimulated ROS production in neutrophils. J Cell Sci 2011; 124: 1973–1983.

Ganesan R, Mahankali M, Alter G, Gomez-Cambronero J. Two sites of action for PLD2 inhibitors: the enzyme catalytic center and an allosteric, phosphoinositide binding pocket. Biochim Biophys Acta BBA - Mol Cell Biol Lipids 2015; 1851: 261–272.

Mahankali M, Henkels KM, Gomez-Cambronero J. A GEF-to-phospholipase molecular switch caused by phosphatidic acid, Rac and JAK tyrosine kinase that explains leukocyte cell migration. J Cell Sci 2013; 126: 1416–1428.

Gomez-Cambronero J. Biochemical and cellular implications of a dual lipase-GEF function of phospholipase D2 (PLD2). J Leukoc Biol 2012; 92: 461–467.

Zheng Y, Du G. Phosphatidic acid signaling regulation of Ras superfamily of small guanosine triphosphatases. Biochim Biophys Acta 2009; 1791: 850–855.

Buxhofer-Ausch V, Olaoydu D, Gisslinger B, Schalling M, Frantal S, Thiele J et al. Decanucleotide insertion polymorphism of F7 significantly influences the risk of thrombosis in patients with essential thrombocytopenia. Eur J Haematol 2014; 93: 103–111.

He H, Xu Y-J, Yin Y-J, Li X, Gu J, Xu X-J et al. Association of nitric oxide synthase 3 (NOS3) 894 G>T polymorphism with prognostic outcomes of antracycline in Chinese patients with acute myeloid leukemia. Clin Exp Pharmacol Physiol 2014; 41: 400–407.

Boissinot M, Vilaine M, Hermouet S. The hepatocyte growth factor (HGF)/met axis: a neglected target in the treatment of chronic myeloproliferative neoplasms? Cancers 2014; 6: 1631–1669.

Spencer IA, Ferraro F, Roussakis E, Klein A, Wu J, Runnels JM et al. Direct measurement of local oxygen concentration in the bone marrow of live animals. Nature 2014; 508: 269–273.

Lu Y-C, Weng W-C, Lee H. Functional roles of calreticulin in cancer biology. BioMed Res Int 2015; 2015: 526524.

Britschgi C, Jenal M, Rizzi M, Mueller BL, Torbett BE, Andrees A-C et al. HIC1 tumour suppressor gene is suppressed in acute myeloid leukaemia and induced during granulocytic differentiation. Br J Haematol 2008; 141: 179–187.

Melki JR, Vincent PC, Clark SJ. Cancer-specific region of hypermethylation identified within the HIC1 putative tumour suppressor gene in acute myeloid leukaemia. Leukemia 1999; 13: 877–883.

Roodink L, Versluijs K, Raats J, Leeanders WPJ. Plexin D1 is ubiquitously expressed on tumor vessels and tumor cells in solid malignancies. BMC Cancer 2009; 9: 297.

Luchino J, Hocine M, Amouroux M-C, Gibert B, Bernet A, Ruyet A et al. Semaphorin 3E suppresses tumor cell death triggered by the plexin D1 dependence receptor in metastatic breast cancers. Cancer Cell 2013; 24: 673–685.

Tamagnone L, Rehman M. To die or not to die: Sema3E rules the game. J Cell Mol Med 2013; 17: 685–699.

This work is licensed under a Creative Commons Attribution 4.0 International license. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/